Dr Reddy's Ties Up with Gilead for HIV Drug Lenacapavir Commercialisation

Dr Reddy's Laboratories has partnered with Gilead Sciences to manufacture and commercialize the HIV drug Lenacapavir in India and 120 other countries. The deal involves a non-exclusive voluntary licensing agreement and covers both treatment and the potential prevention of HIV. The initiative aims to benefit low- and middle-income countries with high HIV burdens.

Dr Reddy's Laboratories on Wednesday announced a collaboration with Gilead Sciences to manufacture and commercialize the HIV drug Lenacapavir across India and 120 other nations.

The Hyderabad-based pharmaceutical firm entered into a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the production of the USFDA-approved medication, intended for treating HIV-1 infection in heavily treatment-experienced adults.

Dr Reddy's will handle the technology transfer, bioequivalence studies, product registration, and market launch. The agreement also includes potential approval for the drug's preventive use in 120 countries.

(With inputs from agencies.)